NCT00003670View on ClinicalTrials.gov

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

October 31, 1998

Study Completion Date

January 31, 2001

Conditions

Ovarian CancerPrimary Peritoneal Cavity Cancer

Interventions

DRUG

arzoxifene hydrochloride

Trial Locations (4)

19001

Abington Memorial Hospital, Abington

65203

Ellis Fischel Cancer Center - Columbia, Columbia

77030

University of Texas - MD Anderson Cancer Center, Houston

27599-7295

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00003670 - Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter